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Abstract
Background: Genetic factors related to the regulation of apoptosis in schizophrenia patients may be involved in a
reduced vulnerability to cancer. XRCC4 is one of the potential candidate genes associated with schizophrenia
which might induce colorectal cancer resistance.
Methods: To examine the genetic association between colorectal cancer and schizophrenia, we analyzed five SNPs
(rs6452526, rs2662238, rs963248, rs35268, rs2386275) covering ~205.7 kb in the region of XRCC4.
Results: We observed that two of the five genetic polymorphisms showed statistically significant differences
between 312 colorectal cancer subjects without schizophrenia and 270 schizophrenia subjects (rs6452536, p =
0.004, OR 0.61, 95% CI 0.44-0.86; rs35268, p = 0.028, OR 1.54, 95% CI 1.05-2.26). Moreover, the haplotype which
combined all five markers was the most significant, giving a global p = 0.0005.
Conclusions: Our data firstly indicate that XRCC4 may be a potential protective gene towards schizophrenia,
conferring reduced susceptibility to colorectal cancer in the Han Chinese population.
Background
The correlation between schizophrenia and cancer has
been investigated for over a century, but the research on
this epidemiological puzzle has produced contradictory
findings [1,2]. According to recent studies, reduced risk
and incidence for cancer were found to be associated
with schizophrenia [3-5]. The explanations proposed for
this finding have included genetic factors, neuroleptic
medication, and environmental aspects [5-7]. The
genetic basis of this lower risk has been ascribed to spe-
cific protective mechanism against cancer found in schi-
zophrenia patients [7]. But until now p53 is the only
gene to have been reported as being involved in this
protective mechanism [8]. Recently, Park et al. [8] made
a genetic association analysis of SNPs in the p53 gene
between 104 lung cancer patients and 179 schizophrenia
patients, and the results indicated that the p53 poly-
morphisms might be a genetic marker for lower sus-
ceptibility to lung cancer in schizophrenia patients.
The X-ray repair complementing defective repair in
Chinese hamster cells 4 (XRCC4) gene is located on
chromosome 5q14.2, which showed loss of heterozygosity
(LOH) in sporadic colorectal cancer (Ratio 37.7%), and
high ratio LOH indicates the presence of tumor suppres-
sor locus. Moreover, in this region nearby allelic losses
for tumor suppressor genes have been suggested as being
associated with colorectal tumorigenesis [9]. The protein
encoded by XRCC4 consists of 336 amino acid residues
distributed among 8 exons, and has a long helical stem
domain responsible for multimerization and interaction
w i t hD N Al i g a s eI V[ 1 0 ] .B yf o r m i n gac o m p l e xw i t h
DNA ligase IV and DNA-dependent protein kinase,
XRCC4 functions in the repair of DNA double-strand
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and the completion of V(D)J recombination events [11].
The NHEJ pathway is required not only for normal
development but also for suppression of tumors. Since it is
one of the ubiquitous NHEJ components [12], XRCC4
might be considered as a potential tumor suppressor gene
in several types of carcinoma. Disruption of XRCC4 in
mouse embryonic cells leads to chromosomal instability,
radiation hypersensitivity, and severely impaired V(D)J
recombination [13]. In addition, Yan et al. have suggested
that XRCC4 and, by extension, the NHEJ pathway is cru-
cial for suppressing genomic instability in neuronal cells of
mice [14]. Recently, Bau et al. have reported significant
association of SNPs in the XRCC4 gene with colorectal
cancer, indicating that the genetic polymorphisms of
XRCC4 might be involved in colorectal carcinogenesis
[15]. On the basis of the above evidence and the findings
of Sugai et al., we deduced that XRCC4 might be involved
in the development of colorectal carcinoma. Moreover,
data from recent reports have revealed schizophrenia sus-
ceptibility loci on chromosome 5q14 [16,17], which is
in the vicinity of the XRCC4 gene. In mice, XRCC4-
deficiency leads to massive neuronal apoptosis [12].
We therefore concluded that variants within the
XRCC4 gene might confer genetically reduced suscept-
ibility to colorectal cancer among patients with schizo-
phrenia. To examine this assumption, we investigated
five genetic polymorphisms (rs6452526, rs2662238,
rs963248, rs35268 and rs2386275) between Chinese col-
orectal cancer subjects without schizophrenia and schi-
zophrenia subjects, a genetic association strategy similar
to that used by Park et al. [8].
Methods
Subjects
A total of 312 sporadic colorectal cancer patients (178
male and 134 female, age 61.23 ± 14.03 years) and 270
schizophrenia patients (191 male and 79 female, age
57.25 ± 11.55 years) were recruited for this study. All
the CRC patients underwent curative resection between
1999 and 2007 at the surgical department of the Shang-
hai First People’s Hospital or the Shanxi People’s Hospi-
tal, China. The cancerous tissue and adjacent normal
control tissue (>10 cm) were immediately frozen in
liquid nitrogen. The pathologic tumor staging was per-
formed according to Duke’s criteria. The DSM-III-R was
used as the diagnostic criterion for schizophrenia
patients, all of whom were from Shanghai and were Han
Chinese in origin. Two independent psychiatrists made
a final diagnosis on the basis of interview data and hos-
pital case notes. All subjects gave informed consent for
the genetic analysis, which was reviewed and approved
by the ethics committee of the Human Genetics Center
in Shanghai. DNA was extracted using standard meth-
ods with phenol/chloroform purification.
Genotyping
We genotyped five genetic polymorphisms, namely
rs963248, which had been reported by Hayden et al. [11],
and four other SNPs (rs6452526, rs2662238, rs35268 and
rs2386275) from the HapMap project database http://
www.hapmap.org and dbSNP http://www.ncbi.nlm.nih.
gov/SNP/ to cover a ~205.7 kb region of XRCC4. All five
markers are intronic SNPs (Figure 1). We genotyped
these SNPs by the TaqMan® assay method using the ABI
7900 DNA detection system (Applied Biosystems, Foster
City, California). All probes and primers were designed
by the Assay-on-Design service of Applied Biosystems.
The standard PCR was performed using the Taqman®
Universal PCR Master Mix (Applied Biosystems) reagent.
Statistical analysis
We analyzed Hardy-Weinberg equilibrium, allelic and gen-
otypic distributions on http://202.120.31.137/myanalysis.
Figure 1 The five SNPs selected among the genomic region of XRCC4.
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Page 2 of 6php [18], a user-friendly platform which integrates effi-
cient analysis tools for association studies. Monte
Carlo simulation strategy and c
2 test were used to
compare the discrepancies of allele and genotype fre-
quencies between CRC and schizophrenia patients [19].
We estimated linkage disequilibrium (LD) using “D” as
the standardized measure, for all possible pairs of SNP
loci. We corrected the P values of association analysis
for multiplicity using a false discovery rate (FDR) con-
trolling procedure [20]. Power calculations were per-
formed using the G*Power program [21]. All the p
values in the study were two-tailed and the significance
level was set at p=0.05. Results were also expressed
in terms of the odds ratio (OR) and 95% confidence
interval (CI), which were calculated on the website
http://www.hutchon.net/ConfidOR.htm. The program
UNPHASED was used to estimate haplotype frequen-
cies [22].
Results
Genotype distributions of all five SNPs showed no sig-
nificant deviations from Hardy-Weinberg equilibrium in
either CRC or schizophrenia subjects. The allele and
genotype frequencies of the SNPs are listed in Table 1.
The power of rs6452526, rs2662238, rs963248, rs35268
and rs2386275 were of 0.767, 0.782, 0.852, 0.695 and
0.844 respectively, with an OR of 1.5 (95% CI). For
genetic polymorphisms rs6452526, there were statisti-
cally significant differences in allele frequencies between
the 312 CRC subjects and the 270 schizophrenia sub-
jects (p = 0.004, p = 0.020, after the FDR correction).
The T allele and TT genotype of rs6452526 were signifi-
cantly less common in the CRC group compared to the
schizophrenia group (allele, 13.4% versus 20.2%, OR
0.61, 95% CI 0.44-0.86; genotype, 2.3% versus 5.3%).
Moreover, the allele frequency of rs35268 showed signif-
icant difference between the CRC and schizophrenia
groups (p = 0.028, p = 0.070, after the FDR correction).
The T allele of this marker was more common in CRC
subjects than in schizophrenia subjects (90.9% versus
86.6%, OR 1.54, 95% CI 1.05-2.26).
After analyzing linkage disequilibrium for each pair of
the SNPs in the CRC and schizophrenia subjects (Table
2), two groups of markers (rs6452526-rs2662238 and
rs963248-rs35268) were observed to be in strong LD
respectively [23]. We therefore adopted the haplotype
distributions for these SNPs in the later analysis. Haplo-
types were omitted from analysis if the estimated haplo-
type probabilities were less than 3% in either the CRC
or schizophrenia groups.
We selected only those haplotypes with significant fre-
quency discrepancies between CRC and schizophrenia
subjects (Table 3) for presentation. Haplotype analysis
of these polymorphisms revealed some significant global
pv a l u e s( T a b l e4 ) .O n et w o - S N P - b a s e dh a p l o t y p ea n d
one five-SNP-based haplotype showed significant fre-
quency difference between the CRC and schizophrenia
groups. The haplotype combining all five markers was
the most significant, giving a global p = 0.0005 (p =
0.0141, after the FDR correction). As its frequency was
greater in the CRC group than in the schizophrenia
group, the haplotype C-G-A-T-G (rs6452526-rs2662238-
rs963248-rs35268-rs2386275) was found to be correlated
with an increased odds ratio for CRC (p =0 . 0 0 1 ,O R
2.07, 95% CI 1.32-3.24, p = 0.025, after the FDR correc-
tion). However, none of other significant haplotypes sur-
vived the FDR correction.
Table 1 Allele and genotype frequencies of 5 SNPs among colorectal cancer and schizophrenia patients
SNP ID genotype frequency(%) p value* FDR adjusted allele frequency(%) X
2 p value* FDR adjusted Odds Ratio (95%CI)
rs6452526 CC CT TT C T
CRC 194(75.5) 57(22.2) 6(2.3) 0.021 0.105 455(86.6) 69(13.4) 8.276 0.004 0.020 0.61(0.44-0.86)
SZ 159(64.9) 73(29.8) 13(5.3) 391(79.8) 99(20.2)
rs2662238 AA AG GG A G
CRC 12(4.3) 77(27.4) 192(68.3) 0.895 0.895 101(18.0) 461(82.0) 0.222 0.637 0.637 0.93(0.68-1.26)
SZ 13(5.0) 74(28.2) 175(66.8) 100(19.1) 424(80.9)
rs963248 AA AG GG A G
CRC 29(10.9) 105(39.6) 131(49.4) 0.296 0.493 163(30.8) 367(69.2) 1.303 0.254 0.317 1.17(0.89-1.53)
SZ 18(7.0) 105(41.0) 133(52.0) 141(27.5) 371(72.5)
rs35268 CC CT TT C T
CRC 2(0.7) 47(16.8) 230(82.4) 0.078 0.194 51(9.1) 507(90.9) 4.834 0.028 0.070 1.54(1.05-2.26)
SZ 3(1.2) 62(24.4) 189(74.4) 68(13.4) 440(86.6)
rs2386275 AA AG GG A G
CRC 124(52.3) 86(36.3) 27(11.4) 0.416 0.520 334(70.5) 140(29.5) 1.583 0.208 0.347 1.20(0.91-1.58)
SZ 146(56.2) 93(35.8) 21(8.1) 385(74.0) 135(26.0)
*Pearson’s p value, SNP = single nucleotide polymorphism, FDR = false discovery rate, CI = confidence interval, CRC = colorectal cancer, SZ = schizophrenia.
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Page 3 of 6In the power calculations using the G*Power 3 pro-
gram, our sample size had greater than 90% power to
detect a significant (a < 0.05) association for alleles,
genotypes and haplotypes when an effect size index of
0.1 (corresponding to a “weak” gene effect) was used.
Discussion
The question whether schizophrenia is linked to a
decreased risk of developing cancer has been the subject
of considerable research over a number of decades. The
debate has centered on the incidence of malignancies in
patients with schizophrenia which have been variously
reported to be higher, lower, or similar to that in the
general population. However, the majority of studies in
the last decade have suggested that schizophrenia
patients are protected against cancer in general [3-5].
Several possible explanations have been offered for the
evidence that cancer risk and incidence are reduced in
patients with schizophrenia. In one of the earlier studies,
Mortensen observed a lower risk of prostate cancer
among schizophrenia patients who had been exposed to
prolonged neuroleptic medication [6]. More recent
theories have focused on the possibility that increased
apoptosis could account for the neurodevelopmental
abnormalities as well as tumor resistance linked to schi-
zophrenia [7], an explanation supported by Park et al. in
a Korean cohort [8]. XRCC4 encodes a nuclear phospho-
protein that multimerizes and interacts with DNA Ligase
4 and DNA-dependent protein kinase, playing a critical
role in the non-homologous end joining (NHEJ) pathway
[11]. In mice, XRCC4-deficiency is embryonically lethal
with a massive neuronal apoptosis, and XRCC4 has been
observed to interplay with p53 in the regulation of apop-
tosis, indicating that XRCC4 is crucial for maintaining
genomic stability and for the suppression of tumors [12].
Thus, XRCC4 might be a potential candidate gene for
the hypothesis that schizophrenia offers reduced suscept-
ibility to malignancy.
In the present study, our data based on Han Chinese
samples provide further support for the assumption that
XRCC4 might be involved in a potential protective
mechanism against cancer in schizophrenia patients.
We conducted the genetic analysis by genotyping five
SNPs, including one SNPs previously investigated by
Hayden et al. [11], and four other SNPs selected from
the HapMap project database http://www.hapmap.org
and dbSNP http://www.ncbi.nlm.nih.gov/SNP/. At two
of the five markers (rs6452526 and rs35268) there were
statistically significant discrepancies of allele or geno-
type frequencies between CRC and schizophrenia sub-
jects. We observed that the T allele of r6452526 was
less frequent in CRC than in schizophrenia subjects
(OR 0.61, 95% CI 0.44-0.86, p = 0.004, p = 0.020,
after the FDR correction), indicating that it might be a
protective factor for schizophrenia patients against
CRC; whereas the higher frequency of the T allele for
rs35268 in CRC than in schizophrenia subjects (OR
1.54, CI 1.05-2.26, p = 0.028, p = 0.070, after the FDR
correction) implies that the T allele might be a risk
allele for CRC.
Table 2 Estimation of linkage disequilibrium between the
5 SNPs
rs6452526 rs2662238 rs963248 rs35268 rs2386275
rs6452526 0.99 0.08 0.28 0.12
rs2662238 0.90 0.17 0.31 0.15
rs963248 0.00 0.00 0.75 0.42
rs35268 0.05 0.05 0.03 0.10
rs2386275 0.01 0.01 0.16 0.00
For each pair of SNPs, D’ > 0.7 are shown in boldface,
D’ values are shown above and r
2 values below the diagoal,
SNP = single nucleotide polymorphism.
Table 3 Estimated haplotype frequencies and association significance
Haplotype* Haplotype frequency(%) X
2 p value Odds Ratio (95%CI)
rs6452526 rs2662238 rs963248 rs35268 rs2386275 CRC SZ
T A 63.97(13.0) 98.00(20.2) 8.251 0.004 0.61(0.43-0.86)
C G 415.97(84.2) 386.00(79.8) 8.251 0.004 1.65(1.17-2.33)
G C 40.64(8.1) 61.29(12.5) 5.118 0.024 0.62(0.41-0.94)
T A G T A 18.46(5.2) 45.45(10.2) 6.693 0.010 0.48(0.28-0.85)
T A G C A 5.22(1.5) 20.07(4.5) 5.918 0.015 0.32(0.12-0.84)
C G A T G 54.49(15.2) 36.21(8.2) 10.445 0.001 2.07(1.32-3.24)
*Haplotypes were omitted from analysis if the estimated haplotype probabilities were less than 5%.
CI = confidence interval, CRC = colorectal cancer, SZ = schizophrenia.
Table 4 Global p values of estimated haplotypes of the 5
SNPs within XRCC4
Haplotype Global p
value*
FDR
adjusted
rs6452526-rs2662238 0.0041 0.0212
rs963248-rs35268 0.0599 0.0708
rs6452526-rs2662238-rs963248-rs35268-
rs2386275
0.0005 0.0141
*Pearson’s p value, FDR = false discovery rate, statistical significance set at
p < 0.05,
SNP = single nucleotide polymorphism.
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Page 4 of 6Since haplotypes constructed from closely located
markers will typically increase the statistical power for
association with the disease, we performed haplotype
analysis in SNPs with strong linkage disequilibrium (D’
> 0.7). Our results indicated that one two-SNP-based
haplotype and one five-SNP-based haplotype showed
significant global frequency difference between the CRC
and schizophrenia groups (Table 4). The most signifi-
cant window spanned all five SNPs giving a global
p = 0.0005 (p = 0.0141, after the FDR correction). In
addition, we observed that the most significant haplotype
C-G-A-T-G (rs6452526-rs2662238-rs963248-rs35268-
rs2386275, OR 2.07, 95% CI 1.32-3.24, p = 0.001,
p = 0.025, after the FDR correction) was twice as com-
m o ni nt h eC R Cg r o u p( 1 5 . 2 % )a si nt h es c h i z o p h r e n i a
group (8.2%), suggesting that C-G-A-T-G is a risk haplo-
type for CRC. In addition, we have compared the
frequencies of C-G-A-T-G haplotype between CRC
patients and normal controls, but the individual P value
showed there was no difference.
Park et al. using genetic association analysis, showed
that p53, as a protective gene, induced a lower incidence
of lung cancer among Korean patients with schizophrenia
[8]. Using a similar research strategy, we found that poly-
morphisms of XRCC4 may confer genetically reduced
susceptibility to CRC among Chinese schizophrenia
patients. Compared to the study of Park et al. our sample
was twice as large and involved better age-matched sub-
jects, thus decreasing the possibility of false-positive
results [24]. However, the genetic contribution to this
reduced risk for CRC among schizophrenia subjects is
likely to involve a series of susceptibility loci, each influ-
encing but not determining overall risk. In addition, our
sample size is relatively small, thus additional replication
studies using more SNPs in large non-Asian samples are
needed. Genetic, environmental, and pharmacological
influences are all thought to be contributing factors,
which poses a major challenge for solving this epidemio-
logical puzzle [5-7].
Conclusions
In summary, our results provide a first indication that
XRCC4 might be a potential protective gene with respect
to schizophrenia, conferring decreased susceptibility to
colorectal cancer in the Han Chinese population. Genetic
studies to date have focused on subjects of Asian ethni-
city, and further research needs to be undertaken in
other ethnic groups. Replicating studies with more mar-
kers and with larger samples will be necessary to clarify
the correlation between schizophrenia and cancer.
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